| pubmed-article:14681724 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:14681724 | lifeskim:mentions | umls-concept:C0001483 | lld:lifeskim |
| pubmed-article:14681724 | lifeskim:mentions | umls-concept:C0017296 | lld:lifeskim |
| pubmed-article:14681724 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:14681724 | lifeskim:mentions | umls-concept:C0920533 | lld:lifeskim |
| pubmed-article:14681724 | lifeskim:mentions | umls-concept:C1704259 | lld:lifeskim |
| pubmed-article:14681724 | lifeskim:mentions | umls-concept:C1160185 | lld:lifeskim |
| pubmed-article:14681724 | lifeskim:mentions | umls-concept:C1705987 | lld:lifeskim |
| pubmed-article:14681724 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:14681724 | pubmed:dateCreated | 2003-12-18 | lld:pubmed |
| pubmed-article:14681724 | pubmed:abstractText | Adenoviral gene expression that is repressed by p53 in nontransformed cells could provide a tumor-specific gene therapy approach for a large subset of tumors. Adenoviral infection in vivo induces stabilization of p53, which can be utilized for a strategy that includes p53-dependent expression of a transcriptional repressor and a target promoter,which is highly susceptible for transcriptional repression. Therefore, we constructed different versions of CMV-promoters (CMVgal) with binding sites for GAL4-DBD and investigated 11 GAL4-DBD fusion proteins to elucidate the most effective repressor domain to silence CMVgal activity. The transcriptional repressor GAL4-KRAB-A under control of a p53-dependent promoter facilitates strong CMVgal-mediated gene expression specifically in p53 mutant cells by a double-recombinant adenoviral vector (Ad-RGCdR). GAL4-KRAB-A mediates strong transcriptional repression of Ad-RGCdR in p53 wild-type cells, which could be further enhanced by preactivation of p53-signalling following low-dose chemotherapy prior to adenoviral infection. By utilizing p53 signalling involved in chemotherapy and adenoviral infection, more than 99% of Ad-RGCdR gene expression could be repressed in p53 wild-type cells. Controlled gene expression from CMVgal promoters by transcriptional repression utilizing functional p53 signalling thus provides a very effective tool for tumor-specific adenoviral gene therapy. | lld:pubmed |
| pubmed-article:14681724 | pubmed:language | eng | lld:pubmed |
| pubmed-article:14681724 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14681724 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:14681724 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14681724 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14681724 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14681724 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14681724 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:14681724 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:14681724 | pubmed:issn | 0929-1903 | lld:pubmed |
| pubmed-article:14681724 | pubmed:author | pubmed-author:WirthThomasT | lld:pubmed |
| pubmed-article:14681724 | pubmed:author | pubmed-author:TrautweinChri... | lld:pubmed |
| pubmed-article:14681724 | pubmed:author | pubmed-author:KubickaStefan... | lld:pubmed |
| pubmed-article:14681724 | pubmed:author | pubmed-author:KühnelFlorian... | lld:pubmed |
| pubmed-article:14681724 | pubmed:author | pubmed-author:ZenderLarsL | lld:pubmed |
| pubmed-article:14681724 | pubmed:author | pubmed-author:MannsMichaelM | lld:pubmed |
| pubmed-article:14681724 | pubmed:author | pubmed-author:SchulteBerndB | lld:pubmed |
| pubmed-article:14681724 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:14681724 | pubmed:volume | 11 | lld:pubmed |
| pubmed-article:14681724 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:14681724 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:14681724 | pubmed:pagination | 28-40 | lld:pubmed |
| pubmed-article:14681724 | pubmed:dateRevised | 2009-11-3 | lld:pubmed |
| pubmed-article:14681724 | pubmed:meshHeading | pubmed-meshheading:14681724... | lld:pubmed |
| pubmed-article:14681724 | pubmed:meshHeading | pubmed-meshheading:14681724... | lld:pubmed |
| pubmed-article:14681724 | pubmed:meshHeading | pubmed-meshheading:14681724... | lld:pubmed |
| pubmed-article:14681724 | pubmed:meshHeading | pubmed-meshheading:14681724... | lld:pubmed |
| pubmed-article:14681724 | pubmed:meshHeading | pubmed-meshheading:14681724... | lld:pubmed |
| pubmed-article:14681724 | pubmed:meshHeading | pubmed-meshheading:14681724... | lld:pubmed |
| pubmed-article:14681724 | pubmed:meshHeading | pubmed-meshheading:14681724... | lld:pubmed |
| pubmed-article:14681724 | pubmed:meshHeading | pubmed-meshheading:14681724... | lld:pubmed |
| pubmed-article:14681724 | pubmed:meshHeading | pubmed-meshheading:14681724... | lld:pubmed |
| pubmed-article:14681724 | pubmed:meshHeading | pubmed-meshheading:14681724... | lld:pubmed |
| pubmed-article:14681724 | pubmed:meshHeading | pubmed-meshheading:14681724... | lld:pubmed |
| pubmed-article:14681724 | pubmed:meshHeading | pubmed-meshheading:14681724... | lld:pubmed |
| pubmed-article:14681724 | pubmed:meshHeading | pubmed-meshheading:14681724... | lld:pubmed |
| pubmed-article:14681724 | pubmed:meshHeading | pubmed-meshheading:14681724... | lld:pubmed |
| pubmed-article:14681724 | pubmed:meshHeading | pubmed-meshheading:14681724... | lld:pubmed |
| pubmed-article:14681724 | pubmed:meshHeading | pubmed-meshheading:14681724... | lld:pubmed |
| pubmed-article:14681724 | pubmed:meshHeading | pubmed-meshheading:14681724... | lld:pubmed |
| pubmed-article:14681724 | pubmed:meshHeading | pubmed-meshheading:14681724... | lld:pubmed |
| pubmed-article:14681724 | pubmed:meshHeading | pubmed-meshheading:14681724... | lld:pubmed |
| pubmed-article:14681724 | pubmed:meshHeading | pubmed-meshheading:14681724... | lld:pubmed |
| pubmed-article:14681724 | pubmed:meshHeading | pubmed-meshheading:14681724... | lld:pubmed |
| pubmed-article:14681724 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:14681724 | pubmed:articleTitle | Tumor-specific adenoviral gene therapy: transcriptional repression of gene expression by utilizing p53-signal transduction pathways. | lld:pubmed |
| pubmed-article:14681724 | pubmed:affiliation | Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Carl Neuberg Str. 1, 30625 Hannover, Germany. | lld:pubmed |
| pubmed-article:14681724 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:14681724 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14681724 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14681724 | lld:pubmed |
